After a Scottish aye, NICE says no to Lynparza for prostate cancer -
Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet f
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - ScienceDirect
Dosing | Bevacizumab | Lynparza (olaparib)
IJMS | Free Full-Text | Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy